Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Long-patch Base Excision Repair

Long-patch Base Excision Repair

Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.

Targeted oncology·2022

Same author

Correction to: Siponimod: A Review in Secondary Progressive Multiple Sclerosis.

CNS drugs·2021

Same author

Opicapone: A Review in Parkinson's Disease.

CNS drugs·2021

Same author

Lumasiran: First Approval.

Drugs·2021

Same author

Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.

Targeted oncology·2020

Same author

Siponimod: A Review in Secondary Progressive Multiple Sclerosis.

CNS drugs·2020

Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026

Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026

Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026

Same journal

Relacorilant: First Approval.

Drugs·2026

Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026

Same journal

Linerixibat: First Approval.

Drugs·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 20, 2026

Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases

Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases

Published on: August 2, 2022

Prothrombin complex concentrate (Beriplex P/N).

Lesley J Scott¹

¹Adis, a Wolters Kluwer Business, Auckland, New Zealand. demail@adis.co.nz

|September 15, 2009

Summary

This summary is machine-generated.

Beriplex P/N, a plasma-derived concentrate, effectively normalizes coagulation and controls bleeding in adults. It is also used for vitamin K-dependent factor deficiencies when specific factors are unavailable.

More Related Videos

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

Polyelectrolyte Complex for Heparin Binding Domain Osteogenic Growth Factor Delivery

Polyelectrolyte Complex for Heparin Binding Domain Osteogenic Growth Factor Delivery

Published on: August 22, 2016

Related Experiment Videos

Last Updated: Jun 20, 2026

Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases

Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases

Published on: August 2, 2022

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

Polyelectrolyte Complex for Heparin Binding Domain Osteogenic Growth Factor Delivery

Polyelectrolyte Complex for Heparin Binding Domain Osteogenic Growth Factor Delivery

Published on: August 22, 2016

Area of Science:

Hematology
Pharmacology

Background:

Beriplex P/N is a prothrombin complex concentrate derived from human plasma.
It contains vitamin K-dependent coagulation factors (II, VII, IX, X) and proteins C and S.

Purpose of the Study:

To evaluate the efficacy and safety of Beriplex P/N in adult patients.
To assess its use in normalizing international normalized ratios (INR) and controlling bleeding.
To review its effectiveness in treating congenital deficiencies of vitamin K-dependent factors.

Main Methods:

Analysis of data from prospective, noncomparative clinical studies (n=8-43).
Review of extensive clinical experience spanning over a decade.
Evaluation of safety and tolerability of intravenous Beriplex P/N infusions.

Main Results:

Rapid and sustained normalization of elevated INR was observed.
Effective bleeding control was achieved in adult patients.
Beriplex P/N demonstrated efficacy in treating congenital deficiencies when specific factor products were unavailable.

Conclusions:

Intravenous Beriplex P/N is effective for INR normalization and bleeding control in adults.
It serves as a valuable treatment option for vitamin K-dependent factor deficiencies.
Beriplex P/N was generally well-tolerated, with no proven viral transmissions reported in studies.